Intraday Price Movement and Trading Action
On 3 Feb 2026, Lupin Ltd. opened with a significant gap up of 5.67%, setting a positive tone for the trading day. The stock maintained upward momentum, touching an intraday high of Rs 2249.3, which also represents its new 52-week peak. This rally followed two consecutive days of decline, signalling a reversal in trend. The closing price reflected a day change of 3.05%, underscoring sustained demand despite some profit booking in the latter part of the session.
Trading volumes were notably elevated compared to recent sessions, indicating active participation from market participants. Lupin’s price action was supported by its position above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — which collectively suggest a strong technical foundation underpinning the rally.
Sector and Market Context
The Pharmaceuticals & Biotechnology sector, in which Lupin operates, gained 3.06% on the day, closely mirroring Lupin’s own performance. This sector-wide strength contributed to the stock’s positive momentum, with Lupin’s 4.01% one-day gain outpacing the Sensex’s 2.98% rise. Over the past week, Lupin has advanced 3.09%, compared to the Sensex’s 2.74%, and over one month, it has risen 5.02% while the Sensex declined by 1.94%.
Despite the Sensex opening sharply higher by 3,656.74 points, it lost momentum and closed down by 1,231.66 points, settling at 84,091.54, a 2.97% decline. The index remains 2.46% below its 52-week high of 86,159.02. Notably, the Sensex is trading below its 50-day moving average, although the 50DMA remains above the 200DMA, indicating mixed technical signals at the broader market level. Mega-cap stocks led the market today, but Lupin’s performance stands out within the mid-cap pharmaceutical space.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
Longer-Term Performance Metrics
Lupin Ltd.’s recent surge adds to a strong performance trajectory over multiple time frames. The stock has appreciated 11.48% over the past three months, significantly outperforming the Sensex’s marginal 0.15% gain. Year-to-date, Lupin has gained 4.82%, contrasting with the Sensex’s 1.31% decline. Over one year, Lupin’s return stands at 9.13%, slightly ahead of the Sensex’s 8.96%.
Over extended periods, Lupin’s growth has been even more pronounced. The three-year return is an impressive 199.38%, vastly exceeding the Sensex’s 38.23%. Similarly, the five-year gain of 113.33% outpaces the Sensex’s 67.35%. However, over a ten-year horizon, Lupin’s 30.25% return trails the Sensex’s 247.20%, reflecting differing sectoral dynamics and market cycles.
Mojo Score and Rating Update
Lupin Ltd. currently holds a Mojo Score of 74.0, categorised under the ‘Buy’ grade. This represents a downgrade from its previous ‘Strong Buy’ rating, which was adjusted on 28 Jan 2026. The company’s market capitalisation grade remains at 1, indicating a relatively smaller market cap within its peer group. These metrics provide a quantitative assessment of Lupin’s market standing and technical strength as of the latest update.
Want to dive deeper on Lupin Ltd.? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Technical Indicators and Moving Averages
Lupin’s price action today was supported by its position well above all major moving averages. Trading above the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages suggests a strong upward trend and positive momentum. This technical alignment often signals sustained buying interest and can act as support levels in case of short-term corrections.
The stock’s ability to reverse after two days of decline and open with a gap up of 5.67% highlights renewed strength in the trading session. Such moves often attract momentum traders and can lead to further intraday volatility, as observed in Lupin’s session high of Rs 2249.3.
Comparative Sector Performance
The Pharmaceuticals & Biotechnology sector’s gain of 3.06% on the day reflects broad-based strength, with Lupin’s 4.01% one-day increase slightly outperforming the sector average. This outperformance is consistent with Lupin’s recent trend of exceeding sector and benchmark returns across multiple time frames, including one week, one month, and three months.
Such relative strength within the sector underscores Lupin’s prominent role in the pharmaceutical space and its capacity to attract trading interest even amid mixed broader market conditions.
Market Overview and Broader Indices
While Lupin and its sector showed strength, the broader market experienced volatility. The Sensex, after a strong gap up opening, reversed to close down by 2.97%. This divergence highlights Lupin’s resilience and sector-specific momentum despite broader market pressures. The Sensex’s current position below its 50-day moving average, yet with the 50DMA above the 200DMA, indicates a market in a transitional phase, with mega-cap stocks leading gains but mid-cap and sector-specific stocks like Lupin showing differentiated performance.
Summary of Key Metrics
Lupin Ltd. demonstrated a strong intraday performance on 3 Feb 2026, hitting a new 52-week high of Rs 2249.3 with a day change of 3.05%. The stock opened with a gap up of 5.67% and traded above all major moving averages. Its one-day gain of 4.01% outpaced the Sensex’s 2.98% rise, while the Pharmaceuticals & Biotechnology sector gained 3.06%. Over longer periods, Lupin has consistently outperformed the Sensex and its sector peers, supported by a Mojo Score of 74.0 and a current ‘Buy’ grade.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
